InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-02-10 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-10-31 | Lisa McClain(R-MI09) | house | Sale | $1,001 - $15,000 |
| 2025-10-30 | Lisa McClain(R-MI09) | house | Sale | $1,001 - $15,000 |
| 2025-10-30 | Lisa McClain(R-MI09) | house | Purchase | $1,001 - $15,000 |
| 2025-06-09 | Lisa McClain(R-MI09) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Total revenue | $634.0M-11.5% | $716.0M-0.1% | $717.0M+13.6% | $631.0M+13.1% | $558.0M |
| Amortization of acquired intangible assets | $66.0M-48.0% | $127.0M-33.5% | $191.0M+10.4% | $173.0M+143.7% | $71.0M |
| Total cost of revenue | $1.47B-2.5% | $1.51B-14.1% | $1.76B+9.2% | $1.61B+17.5% | $1.37B |
| Gross profit | $2.87B+0.3% | $2.86B+4.3% | $2.74B-7.7% | $2.97B-5.8% | $3.15B |
| Research and development | $967.0M-17.3% | $1.17B-13.7% | $1.35B+2.5% | $1.32B+11.5% | $1.19B |
| Selling, general and administrative | $1.09B-0.5% | $1.09B-32.3% | $1.61B+24.3% | $1.30B-38.0% | $2.09B |
| Goodwill and intangible impairment | $0-100.0% | $1.89B+128.4% | $827.0M-78.9% | $3.91B | $0 |
| Legal contingency and settlement | $10.0M+102.2% | -$456.0M-2380.0% | $20.0M-96.8% | $619.0M | $0 |
| Total operating expense | $2.06B-44.2% | $3.69B-3.1% | $3.81B-46.7% | $7.15B+118.2% | $3.28B |
| Income (loss) from operations | $807.0M+196.9% | -$833.0M+22.1% | -$1.07B | — | — |
| Interest income | $40.0M-13.0% | $46.0M-20.7% | $58.0M+427.3% | $11.0M | $0 |
| Interest expense | -$101.0M-1.0% | -$100.0M-29.9% | -$77.0M-196.2% | -$26.0M+57.4% | -$61.0M |
| Other income (expense), net | $340.0M+216.4% | -$292.0M-906.9% | -$29.0M | — | — |
| Total other income (expense), net | $279.0M+180.6% | -$346.0M-620.8% | -$48.0M | — | — |
| Income (loss) before income taxes | $1.09B+192.1% | -$1.18B-5.6% | -$1.12B | — | — |
| Provision for income taxes | $236.0M+436.4% | $44.0M+0.0% | $44.0M-35.3% | $68.0M-44.3% | $122.0M |
| Net income (loss) | $850.0M+169.5% | -$1.22B-5.3% | -$1.16B | — | — |
| Basic (in dollars per share) | $5.5M+171.1% | -$7.7M-4.8% | -$7.3M+73.8% | -$28.0M-652.3% | $5.1M |
| Diluted (in dollars per share) | $5.5M+170.9% | -$7.7M-4.8% | -$7.3M+73.8% | -$28.0M-655.6% | $5.0M |
| Basic (in shares) | $155.0M-2.5% | $159.0M+0.6% | $158.0M-100.0% | $157.00T+104666566.7% | $150.0M |
| Diluted (in shares) | $156.0M-1.9% | $159.0M+0.6% | $158.0M-100.0% | $157.00T+103973409.9% | $151.0M |
| Product | |||||
| Total revenue | $634.0M-11.5% | $716.0M-0.1% | $717.0M+13.6% | $631.0M+13.1% | $558.0M |
| Cost of revenue | $300.0M-18.3% | $367.0M-6.4% | $392.0M+32.9% | $295.0M+22.4% | $241.0M |
| Service | |||||
| Total revenue | $634.0M-11.5% | $716.0M-0.1% | $717.0M+13.6% | $631.0M+13.1% | $558.0M |
| Cost of revenue | $300.0M-18.3% | $367.0M-6.4% | $392.0M+32.9% | $295.0M+22.4% | $241.0M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Why The Dip In TEM Stock Is A Buying Window
Assessing Illumina (ILMN) Valuation After Earnings Beat Guidance Hike And Expanded Buyback
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)